Navigation Links
Bioheart, Inc. to Transfer to Nasdaq Capital Market
Date:6/10/2008

SUNRISE, Fla., June 10 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT) today announced that it has received approval to transfer the listing of its common stock to the Nasdaq Capital Market. The Company's common stock will be transferred from The Nasdaq Global Market to The Nasdaq Capital Market at the opening of business on Wednesday, June 11, 2008. The Nasdaq Capital Market is a tier of the Nasdaq Stock Market for companies with a lower market capitalization requirement than the Global Market tier. The Company's stock will continue to trade, and benefit from the liquidity provided by the Nasdaq Stock Market.

The listing transfer is in response to a letter dated May 21, 2008 from the Nasdaq Stock Market, Inc. which, as previously announced, notified the Company that it was not in compliance with certain of the continued listing requirements for the Nasdaq Global Market.

Bioheart's trading symbol on The Nasdaq Capital Market will remain 'BHRT.'

About Bioheart, Inc.:

Bioheart, Inc. is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic proteins.

(MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.)


'/>"/>
SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
2. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
3. Bioheart, Inc. Announces Financial Results for First Quarter 2008
4. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
5. Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R)
6. Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
7. Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
8. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
9. Biological electron transfer captured in real time
10. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
11. Easily Lift, Transfer and Reposition Patients with Ground-Breaking Liftaem(TM) System from Smart Medical Technology, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):